Lu-177
Phase 3Small molecule
Lu-177 is one of 13 small molecule programs targeting Neuroendocrine Tumors. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Neuroendocrine Tumors
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Keytruda
Merck & Co.Phase 2
Lenvima
EisaiPhase 2
Verzenio
Eli LillyPhase 2
Cabometyx
Bristol-Myers SquibbPhase 1
Surufatinib
HHutchison Medipharma Limited
Phase 2
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Phase 2
Lu-177
MM.D. Anderson Cancer Center
Phase 3
Lutathera
AAdvanced Accelerator Applications
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu-177. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MM.D. Anderson Cancer Center